Agilon Health, Inc.
AGL · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 2.39B | 111.36M | -105.38M | -106.55M | -6.50 |
| 2023 FY | 4.32B | 69.67M | -232.13M | -262.60M | -16.00 |
| 2024 FY | 6.06B | 4.84M | -292.13M | -260.15M | -15.75 |
| 2025 FY | 5.93B | -188.61M | -421.08M | -405.35M | -24.50 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.70B | 656.86M | 465.30M | 52.57M | 1.04B |
| 2023 FY | 1.74B | 1.08B | 114.33M | 52.31M | 661.84M |
| 2024 FY | 1.73B | 1.26B | 193.86M | 43.96M | 470.95M |
| 2025 FY | 1.27B | 1.14B | 173.71M | 36.82M | 126.73M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -130.81M | -32.66M | -163.47M | — | -547.14M |
| 2023 FY | -156.20M | -30.82M | -187.01M | — | -393.35M |
| 2024 FY | -57.78M | -13.25M | -71.03M | — | 79.53M |
| 2025 FY | -105.76M | -13.24M | -119.01M | — | -20.15M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 6.59B | 6.17B | — | — | — |
| 2023 FY | 5.13B | 5.07B | — | — | — |
| 2024 FY | 780.84M | 630.94M | — | — | — |
| 2025 FY | 285.14M | 148.24M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 1.39B | -52.43M | -116.03M | -104.37M | -6.25 |
| 2025 Q3 | 1.44B | -67.65M | -131.27M | -110.21M | -6.75 |
| 2025 Q4 | 1.57B | -97.64M | -155.76M | -188.88M | -11.50 |
| 2026 Q1 | 1.42B | 58.23M | 10.11M | 29.97M | 1.80 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.71B | 1.30B | 171.42M | 41.37M | 408.93M |
| 2025 Q3 | 1.60B | 1.29B | 171.68M | 37.12M | 306.08M |
| 2025 Q4 | 1.27B | 1.14B | 173.71M | 36.82M | 126.73M |
| 2026 Q1 | 1.50B | 1.32B | 139.99M | 33.40M | 181.43M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -35.09M | -3.25M | -38.34M | — | 32.79M |
| 2025 Q3 | -18.15M | -3.18M | -21.33M | — | 268.00K |
| 2025 Q4 | -20.54M | -17.04M | -37.57M | — | 2.03M |
| 2026 Q1 | 23.73M | -3.10M | 20.63M | — | 37.85M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 951.82M | 821.78M | — | — | — |
| 2025 Q3 | 426.90M | 292.34M | — | — | — |
| 2025 Q4 | 285.59M | 148.69M | — | — | — |
| 2026 Q1 | 131.30M | 24.71M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |